Mannkind Corp (MNKD)
$6.70
0.04 (0.60%)
MNKD Stock Quote Delayed 30 Minutes
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
MNKD stock results show that MannKind beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.77B
PE Ratio
134.00
EPS
0.05
Volume (Avg. Vol.)
2.80M
Day's Range
$6.67 - $6.92
52-Week Range
$3.17 - $6.92
Dividend & Yield
N/A (N/A)
MNKD Stock Predictions, Articles, and Mannkind Corp News
MNKD Stock: The Disappointing FDA News That Has MannKind Shares Diving Today
MannKind (MNKD) stock is taking a beating on Monday after releasing an update to investors concerning news from the FDA for Tyvaso DPI.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! I hope the weekend served you well because we've got pre-market stock movers to start off Monday with!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're at the midpoint of the week now and we're still going strong with a look at the biggest pre-market stock movers for Wednesday.
MannKind Is Crushing It, but Beware or You’ll Be Crushed
Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks.
New Development Partnership Could Pay Off Big for MannKind Stock
MannKind scored a collaboration deal with biotechnology giant, United Therapeutics. This development partnership could pay off big.
Why MannKind Stock Is Skyrocketing Today
MannKind (MNKD) stock was flying high on Tuesday following the announcement of a $45-million deal with United Therapeutics (UTHR).
MannKind Stock Is One Step Away From Obliteration
MNKD stock collapsed after disastrously poor Q2 earnings, but the real story is that MannKind now faces a bankruptcy threat.
MannKind Corporation (MNKD) Stock Slides Despite Q2 Revenue Growth
MannKind Corporation (MNKD) stock was sliding after the bell following the company's quarterly earnings report, which included a year-over-year Afrezza revenue growth of 142%.
Don’t Buy MannKind Corporation Stock Under Any Circumstances
With a depressed share price, sales set to double this year, and a traditionally high-growth sector, it can be tempting to view MannKind Corp. (MNKD) as a bargain. Don’t make that mistake.
Is MannKind Corporation Stock Really Worth the Risk?
Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?
Metrics for Earnings Visibility Keep Mannkind (MNKD) a Sell at recent price of $3.8
The Sell recommendation for Mannkind Corp is the outcome of an analytical process that is proprietary which generated conclusions that were above average in 2 areas: an economic sector rated above average in attractiveness, and a mathematical computation of risk/reward that is better than average; and produced below average results in 4 areas: an industry group rated below average in attractiveness, a ranking in the company's sector that is in the middle third, ranking in the company's industry group that is in the middle third-below average, and analytical scoring that is well below average.
